However, it should be regarded as relevant that Savale et al. (2024), in their proteomic study analyzing blood of PAH patients treated with sotatercept for 24 weeks vs. the placebo, highlighted that not only the activin system was affected but also the expression of proteins that have key roles in inflammation, in cardiovascular and oxidative stress systems, and, last but not least, in cellular metabolism, often dysregulated in PAH patients [34]. This evidence concerns the gene INHBE and pulmonary arterial hypertension.